Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised) Posted byZacks Equity Research January 21, 2022 Leave a comment on Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised) Sanofi’s (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.